Direct comparison
Open-Label vs. Double-Blind Trial Design
When trial blinding isn't feasible or ethical vs. when double-blinding reduces bias, and the real tradeoffs of each design choice.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · included with Regulatory Radar
Ask about Open-Label vs. Double-Blind Trial Design
Ask CASRAI answers research-administration questions and cites the passages behind every claim — and says so when the corpus does not cover something, instead of guessing. It comes with a Regulatory Radar subscription at $29 a month, alongside the daily digest of regulatory changes and the dashboard of what changed.
150 questions a day, on this site, over the API, or inside your own tools through the CASRAI MCP server.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Open-Label, Double-Blind compare side by side?
The table below compares Open-Label, Double-Blind across 6 procurement-relevant dimensions, from who knows treatment assignment through governing guidance.
Side-by-side comparison
| Dimension | Open-Label | Double-Blind |
|---|---|---|
| Who knows treatment assignment | Participant and investigator/care provider both know | Participant and outcomes assessor (often care provider too) are kept unaware |
| Typical use case | Surgical/procedural trials, some oncology trials, trials with distinguishing dosing schedules or physical product characteristics | Drug trials with subjective or assessor-dependent primary endpoints, where matched placebo or double-dummy is feasible |
| Main bias risk | Placebo/expectation effects, assessment bias, differential care/reporting/dropout between arms | Lower risk of these specific biases, though allocation concealment and other design safeguards are still needed separately |
| Design complexity/cost | Lower — no matched placebo, double-dummy, or blinded drug supply chain required | Higher — requires matched/indistinguishable product, restricted randomization-code access, unblinded pharmacist or IRT, emergency unblinding procedures |
| Best-suited endpoints | Objective, hard endpoints (mortality, validated biomarker, blinded central imaging read) | Any endpoint, but especially subjective or discretionary ones (patient-reported outcomes, clinical global impression) |
| Governing guidance | ICH E9 (bias-control principles), ICH E8(R1) (general trial design) | ICH E9 (bias-control principles), ICH E6 (blinding/masking glossary and conduct) |
Common questions
Common questions about Open-Label vs Double-Blind
Is open-label the same as unblinded?
+
Effectively yes for the participant/investigator relationship — the terms are generally used interchangeably. ClinicalTrials.gov specifically labels this masking level "None (Open Label)."
Can a trial be single-blind instead of fully open-label or fully double-blind?
+
Yes. Single-blind designs sit between the two, masking one party (commonly the participant, sometimes the assessor) while the other remains aware of assignment.
Does an open-label design automatically produce weaker evidence?
+
Not automatically — it shifts the burden onto other bias-control measures, such as objective endpoints, independent blinded adjudication, and a rigorously pre-specified analysis plan.
How does blinding status interact with non-inferiority trial design?
+
Independently — a trial's hypothesis framework (superiority vs. non-inferiority) and its blinding status are separate design axes, though they interact in practice: because non-inferiority designs are already more vulnerable to bias that pulls apparent results toward "no difference" (which can spuriously favor a claim of non-inferiority), maintaining rigorous blinding and analysis discipline matters even more in a non-inferiority context. See our Non-Inferiority vs. Superiority Trial Design comparison for the hypothesis-framework side of that decision.
Going deeper
